Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-009221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Jessica A Lake und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology, Oncology, BMT, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: B7 Antigens, Interleukin-8, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Background
Advances in pediatric oncology have occurred for some cancers; however, new therapies for sarcoma have been inadequate. Cellular immunotherapy using chimeric antigen receptor (CAR) T cells has shown dramatic benefits in leukemia, lymphoma, and multiple myeloma but has been far less successful in pediatric solid tumors such as rhabdomyosarcoma (RMS) and osteosarcoma (OS). Balancing issues of “on-target, off-tumor toxicity”, investigators have identified B7-H3 as a broadly expressed tumor antigen with otherwise restricted expression on normal tissues. We hypothesized that rapid homing via a chemokine receptor and CAR engagement through B7-H3 would enhance CAR T cell efficacy in solid tumors.
Methods
We generated B7-H3 CAR T cells that also express the Interleukin-8 (IL-8) receptor, CXCR2. Cytokine production, flow cytometry, Seahorse assays and RNA sequencing were used to compare the B7-H3 CXCR2 (BC2) CAR T cells with B7-H3 CAR T cells. We developed an IL-8 overexpressing human RMS mouse model to test homing and cytotoxicity in vivo.
Results
We demonstrate that IL-8 is expressed by RMS and OS and expression significantly increases after radiation. Overexpression of an IL-8 receptor, CXCR2, on B7-H3 CAR T cells enhances homing into IL-8 expressing tumors, augments T cell metabolism and leads to significant tumor regression.
Conclusion
These findings warrant further investigation into the use of BC2 CAR T cells as a treatment for patients with RMS, OS and other B7-H3-expressing, IL-8 producing solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Hematology, Oncology, BMT, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Department of Pediatric Hematology, Oncology, BMT, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA MICHAEL.VERNERIS@CUANSCHUTZ.EDU.
ORCID-Profile: Jessica A Lake, Michael R Verneris
Förderung
- NIH HHS
- NCI NIH HHS
- NIGMS NIH HHS
- Salah Foundation
- National Institutes of Health
- Colorado Clinical and Translational Sciences Institute
Zitieren
APA
Lake, J. A., Woods, E., Hoffmeyer, E., Schaller, K. L., Cruz-Cruz, J., Fernandez, J., Tufa, D., Kooiman, B., Hall, S. C., Jones, D., Hayashi, M., & Verneris, M. R. (2024). Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009221
Vancouver
Lake JA, Woods E, Hoffmeyer E, Schaller KL, Cruz-Cruz J, Fernandez J, et al. Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009221
BibTeX
@article{Lake2024,
author = {Lake, Jessica A and Woods, Elena and Hoffmeyer, Eric and Schaller, Kristin L and Cruz-Cruz, Joselyn and Fernandez, Joseph and Tufa, Dejene and Kooiman, Benjamin and Hall, Spencer C and Jones, Dallas and Hayashi, Masanori and Verneris, Michael R},
title = {Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-009221}
}
EUVIMED